Gene · 10645
Papers2,799
Newest first. Swiss-Prot's references are curated; PubTator's text mining finds papers that name the gene, not always ones about it.
81 to 100 of 2,799
Download this page as JSON| Title | Journal | Year | PMID | Found by | Source |
|---|---|---|---|---|---|
| Hypercapnia as a Double-Edged Modulator of Innate Immunity and Alveolar Epithelial Repair: A PRISMA-ScR Scoping Review. | Int J Mol Sci | 2025 | 41096887 | PubTator, text mining | PubMed |
| CAMKK2 restored mitochondrial dynamics homeostasis to alleviate pulmonary fibrosis via AMPK/PGC-1α signaling pathway in lung fibroblasts. | Mol Med | 2025 | 41053564 | PubTator, text mining | PubMed |
| Dihydropyrazine activates the CAMKK2-AMPK-ULK1 signaling pathway in human hepatoma HepG2 cells. | J Toxicol Sci | 2025 | 41034044 | PubTator, text mining | PubMed |
| Erianin reverses 5-FU resistance by targeting CALM1/CAMKK2 and activating autophagy in colorectal cancer. | Chem Biol Interact | 2025 | 40976489 | PubTator, text mining | PubMed |
| Effects of G protein-coupled estrogen receptor on hydrogen sulfide production and cystathionine γ-lyase expression in human endothelial cells. | Biochem Pharmacol | 2025 | 40976431 | PubTator, text mining | PubMed |
| CAMKK1 in Obesity and Type 2 Diabetes Mellitus: Evidence of Interaction With Appetite-Regulating, Metabolic and Inflammatory Factors. | Endocrinol Diabetes Metab | 2025 | 40965347 | PubTator, text mining | PubMed |
| The Role of AMPKα in the Mechanism of Development and Treatment of Heart Failure. | Rev Cardiovasc Med | 2025 | 40927091 | PubTator, text mining | PubMed |
| 5-HT regulates resistance to aumolertinib by attenuating ferroptosis in lung adenocarcinoma. | EMBO Mol Med | 2025 | 40897859 | PubTator, text mining | PubMed |
| GPER in metabolic homeostasis and disease: molecular mechanisms, nutritional regulation, and therapeutic potential. | J Transl Med | 2025 | 40859360 | PubTator, text mining | PubMed |
| Piezo1 regulates autophagy in HT22 hippocampal neurons through the Ca2+/Calpain and Calcineurin/TFEB signaling pathways. | PLoS One | 2025 | 40857264 | PubTator, text mining | PubMed |
| Mechanism and cellular actions of the potent AMPK inhibitor BAY-3827. | Sci Adv | 2025 | 40845097 | PubTator, text mining | PubMed |
| Integrative molecular network analysis of genetic risk factors to infer biomarkers and therapeutic targets for rheumatoid arthritis. | PLoS One | 2025 | 40839671 | PubTator, text mining | PubMed |
| The role of probiotics, prebiotics, and synbiotics in the treatment of inflammatory bowel diseases: an overview of recent clinical trials. | Front Syst Biol | 2025 | 40810122 | PubTator, text mining | PubMed |
| Comparative ocular outcomes of tirzepatide versus other anti-obesity medications in people with obesity. | Commun Med (Lond) | 2025 | 40750822 | PubTator, text mining | PubMed |
| Cytosolic DNA and intracellular Ca2+: Maintaining genome stability during replication stress. | DNA Repair (Amst) | 2025 | 40749324 | PubTator, text mining | PubMed |
| PCP4 inhibits the progression of prostate cancer through Ca2+/CAMKK2/AMPK/AR pathway. | Front Immunol | 2025 | 40746562 | PubTator, text mining | PubMed |
| Characterization of novel anoikis-related genes as prognostic biomarkers and key determinants of the immune microenvironment in esophageal cancer. | Front Immunol | 2025 | 40746552 | PubTator, text mining | PubMed |
| A novel 5-protein kinase risk signature for predicting glioma prognosis and immunotherapy responsiveness. | Sci Rep | 2025 | 40715243 | PubTator, text mining | PubMed |
| J147 modulates microglial polarization via CAMKK2/AMPK signaling to ameliorate neuroinflammation. | Biochem Biophys Res Commun | 2025 | 40712391 | PubTator, text mining | PubMed |
| RXRα modulates hepatic stellate cell activation and liver fibrosis by targeting CaMKKβ-AMPKα axis. | Acta Pharm Sin B | 2025 | 40698125 | PubTator, text mining | PubMed |
gene-search-2026-11-11-0.2.0
Sources 12
- ClinicalTrials.gov's posted results, through CTTI's AACTFreely available. Acknowledgement requested
- ChEMBL, through Open TargetsCC BY-SA 3.0
- ClinicalTrials.govNo license stated
- EMBL-EBI's patent proteinsNo added restrictions. Attribution expected
- GenBank's patent filesNo restrictions from NCBI. Submitters may hold rights
- HGNCCC0
- NCBI GenePublic domain (US government)
- NIH's project files and grant-paper linksPublic domain
- Open TargetsCC0 1.0
- PubMedNLM's terms
- PubTator 3Public domain
- UniProtCC BY 4.0
Each source's terms
- ClinicalTrials.gov's posted results, through CTTI's AACTClinicalTrials.gov data via Aggregate Analysis of ClinicalTrials.gov (AACT), CTTI. CTTI makes its materials freely available and requests acknowledgement. https://aact.ctti-clinicaltrials.org/documentation/299
- ChEMBL, through Open TargetsCC BY-SA 3.0, for the parts from ChEMBL. Read on 8 Nov 2026 at https://platform-docs.opentargets.org/licence
- ClinicalTrials.govnone stated
- EMBL-EBI's patent proteinsEMBL-EBI's patent protein files from the EPO, JPO, KIPO and USPTO. EMBL-EBI: "EMBL-EBI itself places no additional restrictions on the use or redistribution of the data available via its Data Resources and Tools other than those provided by the original data owners" and "EMBL-EBI expects attribution (e.g. in publications, services or products) for the use of any of its Data Resources and Tools." Read on 11 Nov 2026 at https://www.ebi.ac.uk/about/terms-of-use
- GenBank's patent filesGenBank's patent files. NCBI: "NCBI places no restrictions on the use or distribution of the GenBank data. However, some submitters may claim patent, copyright, or other intellectual property rights in all or a portion of the data they have submitted." Read on 11 Nov 2026 at https://www.ncbi.nlm.nih.gov/genbank/about/
- HGNCCC0: https://www.genenames.org/about/license/
- NCBI GeneNone named for the file. NCBI says information created by or for the US government on its site is in the public domain, and asks that NLM be acknowledged: https://www.ncbi.nlm.nih.gov/home/about/policies/
- NIH's project files and grant-paper linksPublic domain (NIH RePORTER)
- Open TargetsCC0 1.0. Open Targets asks that users cite its latest paper: Buniello et al. 2025, Open Targets Platform: facilitating therapeutic hypotheses building in drug discovery, Nucleic Acids Research 53(D1):D1467, PMID 39657122. Read on 8 Nov 2026 at https://platform-docs.opentargets.org/licence
- PubMedNLM's terms
- PubTator 3Public domain
- UniProtCC BY 4.0. UniProt's licence file: "All databases and documents in the UniProt FTP directory may be copied and redistributed freely, without advance permission, provided that this copyright statement is reproduced with each copy." UniProt asks that users cite its latest paper: The UniProt Consortium, UniProt: the Universal Protein Knowledgebase in 2025, Nucleic Acids Research 53:D609-D617, https://doi.org/10.1093/nar/gkae1010. Read on 9 Nov 2026 at https://www.uniprot.org/help/license
ClinicalTrials.gov's data carry an international copyright outside the United States: https://clinicaltrials.gov/about-site/terms-conditions.
For software
Read this list from software.
Twenty rows a page, as JSON. No key.
GET https://conductscience.org/api/genes/v1/10645/papers?page=5